↑Nonami A, Kato R, Taniguchi K, Yoshiga D, Taketomi T, Fukuyama S, Harada M, Sasaki A, Yoshimura A (December 2004). "Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells". The Journal of Biological Chemistry. 279 (50): 52543–51. doi:10.1074/jbc.M405189200. PMID15465815.
Further reading
Kato R, Nonami A, Taketomi T, Wakioka T, Kuroiwa A, Matsuda Y, Yoshimura A (March 2003). "Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated Erk activation". Biochemical and Biophysical Research Communications. 302 (4): 767–72. doi:10.1016/S0006-291X(03)00259-6. PMID12646235.
Mizoguchi M, Nutt CL, Louis DN (February 2004). "Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma". Neurogenetics. 5 (1): 81–2. doi:10.1007/s10048-003-0164-x. PMID14618415.
King JA, Corcoran NM, D'Abaco GM, Straffon AF, Smith CT, Poon CL, Buchert M, I S, Hall NE, Lock P, Hovens CM (April 2006). "Eve-3: a liver enriched suppressor of Ras/MAPK signaling". Journal of Hepatology. 44 (4): 758–67. doi:10.1016/j.jhep.2005.10.031. PMID16478641.
Lock P, I ST, Straffon AF, Schieb H, Hovens CM, Stylli SS (December 2006). "Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination". Biochemical and Biophysical Research Communications. 351 (4): 1018–23. doi:10.1016/j.bbrc.2006.10.150. PMID17094949.